Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands [Phase 1]
Phase 1 clinical trial update of LGK974, a Wnt pathway inhibitor, in malignancies dependent on Wnt ligands; the study included several cance…
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) [Phase 1, Phase 2]
AstraZeneca's Dato-DXd is being studied in a Phase 1/2 trial (TROPION-PanTumor02) in Chinese patients with advanced non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer [Phase 1, Phase 2]
Clinical trial update notes the termination of a Phase 1/2 trial evaluating atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant…
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: AVID100 in Advanced Epithelial Carcinomas [Phase 1, Phase 2]
A phase 1/2 trial of AVID100 for advanced epithelial carcinomas was terminated; results were posted in June 2025.
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies [Phase 1]
A Phase Ib safety study of Selinexor (KPT-330) in combination with standard chemotherapy or immunotherapy agents for patients with advanced …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating a circulating tumor DNA–enriched, genomically directed post-neoadjuvant approach for patients with residual tripl…
-
CLINICAL_TRIALS trial_result · 2025-05-28Clinical Trial Update: Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy [Phase 2]
Phase 2 clinical trial evaluating circulating tumor DNA-guided boost therapy for early triple-negative breast cancer patients with residual …
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update reports termination of the NM21-1480 study in adults with advanced solid tumors, including non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors [Phase 1]
Phase 1 dose-escalation study of MNPR-101-PCTA-177Lu in solid tumors is currently recruiting across multiple cancer indications.
-
CLINICAL_TRIALS trial_result · 2025-05-20Clinical Trial Update: Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating cadonilimab combined with chemotherapy as first- or second-line treatment for recurrent or metastatic tr…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). [Phase 1]
Phase 1 study evaluating novel immunotherapy combinations in triple negative breast cancer has been terminated; sponsor is Novartis.
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
This completed clinical trial investigated the relationship between stromal tumor-infiltrating lymphocyte (TIL) levels and immune checkpoint…
-
CLINICAL_TRIALS trial_result · 2025-05-02Clinical Trial Update: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer [Phase 1, Phase 2]
Esperas Pharma completed a Phase 1/2 study of LY2880070 in adults with advanced or metastatic cancer, including colorectal cancer.
-
CLINICAL_TRIALS trial_result · 2025-05-02Clinical Trial Update: Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC [Phase 2]
A Phase 2 clinical trial is investigating trilaciclib combined with an anti-PD-1 antibody and chemotherapy for locally advanced triple-negat…
-
CLINICAL_TRIALS trial_result · 2025-04-15Clinical Trial Update: Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial update evaluating the combination of veliparib and irinotecan hydrochloride in patients with metastatic or unresectable solid …
-
CLINICAL_TRIALS trial_result · 2025-04-15Clinical Trial Update: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer [Phase 2, Phase 3]
The clinical trial evaluating B013 in combination with Nab-Paclitaxel for locally advanced or metastatic triple-negative breast cancer has c…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel [Phase 1]
Phase 1 study evaluating the safety and tolerability of a PARP inhibitor in combination with carboplatin and/or paclitaxel in patients with …
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: PRE-I-SPY Phase I/Ib Oncology Platform Program [Phase 1]
Pre-I-SPY Phase I/Ib oncology platform program update with Phase 1 recruitment ongoing across multiple breast cancer indications, including …
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) [Phase 1]
JEWEL-101 is a Phase 1 trial of XB002 in patients with solid tumors, covering multiple indications. The study has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors [Phase 2]
Phase 2 study evaluating pembrolizumab in patients with advanced solid tumors, including squamous cell carcinoma of the head and neck, tripl…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer [Phase 1, Phase 2]
This document reports the results of a Phase 1/2 clinical trial evaluating the combination of palbociclib and binimetinib in patients with a…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC [Phase 2]
Phase II trial of chiauranib in combination with capecitabine for triple-negative breast cancer was terminated. The update notes the study s…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer [Phase 2]
Phase 2 trial update of AZD5363 (Capivasertib) in combination with paclitaxel for triple-negative and metastatic breast cancer has completed…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC [Phase 2]
Phase 2 clinical trial update indicates the addition of ipatasertib to neoadjuvant chemotherapy plus atezolizumab for triple-negative breast…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC [Phase 2]
Phase 2 study evaluating first-line treatment of relapsed or metastatic triple-negative breast cancer using albumin-bound paclitaxel in comb…